Desidustat in the Management of COVID-19 Patients

Summary

This study is a Phase 2b, Multicenter, Open-label, Randomized, Comparator- Controlled Study to Evaluate the Efficacy and Safety of Desidustat Tablet for the Management of mild, moderate and severe COVID-19 patients. 100 mg of Desidustat will be administered for a period of 14 days along with recommended standard care during the trial.

Timeline

Start

2020-07-25

Primary completion

2021-01-25

Completion

2021-03-31

Drugs

Indications